PRODUCT LITERATURE

Meropenem–vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria

---

Meropenem–vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic
acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemaseproducing carbapenem-resistant Enterobacteriaceae (CRE). The efficacy of meropenem–vaborbactam for
the treatment of complicated urinary tract infections and acute pyelonephritis was demonstrated in a
Phase III trial (TANGO I). Preliminary data from TANGO II, a separate Phase III study, support the efficacy of meropenem–vaborbactam for the treatment of infections caused by CRE. Overall, meropenem–
vaborbactam appears to be safe and well tolerated. It has favorable toxicity, pharmacokinetic and pharmacodynamic profiles compared with other antibiotics with activity against CRE. Meropenem–vaborbactam
is an important addition to the current armamentarium of antimicrobial agents with activity against K.
pneumoniae carbapenemase-producing CRE

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Meropenem
β-lactamase
Gram-negative

Specific Detail Info

Future Microbiol. (2018) 13(9), 971–983

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment